LEXICON PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $678.36M
- P/E (TTM)
- –
- Dividend yield
- –
About Lexicon Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
The company is a biopharmaceutical business focused on discovering, developing, and commercializing pharmaceutical therapies. Its primary commercial product is INPEFA (sotagliflozin), an oral medication prescribed to reduce cardiovascular risks, including heart failure hospitalizations and cardiac death in qualifying adults. The company's clinical pipeline includes sotagliflozin for hypertrophic cardiomyopathy and type 1 diabetes, pilavapadin for diabetic peripheral neuropathic pain, and LX9851 for obesity and related cardiometabolic conditions. It supplies its commercial treatments primarily to major and regional pharmaceutical wholesalers, which distribute the medications to hospitals, retail pharmacies, government institutions, and healthcare providers.
The company operates from its corporate headquarters in The Woodlands, Texas. It maintains commercial and clinical partnerships across international regions, including licensing agreements covering global territories, with regulatory approval for sotagliflozin in the United Arab Emirates and filings in Canada, Australia, and New Zealand. Third-party contractors in North America, Asia, and Europe handle the sourcing, manufacturing, packaging, and logistics for its active pharmaceutical ingredients and finished therapies.
Summary of the business section of Lexicon Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- LEXICON PHARMACEUTICALS, INC.
- Founded
- 1995
- Headquarters
- The Woodlands, TX
- Address
- 2445 Technology Forest Blvd., Suite 1100 77381
- Phone
- (281) 863-3000
- Website
- lexpharma.com
- Employees
- 81, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Houston, Texas
Stock & identifiers
- Ticker
- LXRX
- Exchange
- Nasdaq
- IPO date
- Apr 7, 2000
- Shares outstanding
- 445M, Aug 3, 2026
- Public float
- $170.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-7 reverse, Aug 7, 2015; 1-for-7 reverse, May 21, 2015
- SEC CIK
- 1062822
- CUSIP
- 528872302
- ISIN
- US5288723027
- EIN
- 76-0474169
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael Exton | Chief Executive Officer, Director | 503,263 |
| Brian T. Crum | SVP, General Counsel & Secr. | 330,201 |
| Lisa DeFrancesco | SVP, IR and Corp Comm | 40,251 |
| Rachel Yap Martens | SVP, Partnerships & Corp Strat | 67,090 |
| Suma Gopinathan | SVP, Discovery | 88,520 |
| Scott M. Coiante | SVP, Chief Financial Officer | 105,356 |
| Craig B. Granowitz | SVP, Chief Medical Officer | 432,528 |
| Wendy McDermott | SVP, Human Resources | 277,945 |
| Kristen Alexander | VP, Finance and Accounting | 76,368 |
| Alan J. Main | EVP, Innov & Chem Sciences | 281,391 |
| Brian Corrigan | SVP, Regulatory & QA | – |
| Diane E. Sullivan | Director | 126,122 |
| Judith L. Swain | Director | 174,486 |
| Ivan Cheung | Director | 89,312 |
| Sam L. Barker | Director | 248,771 |
| Raymond Debbane | Director | 51,750,221 |
| Philippe Amouyal | Director | 374,486 |
| Christopher J. Sobecki | Director | 293,177 |
| S.A. Westend | Director | 3,333,376 |
| Administratiekantoor Westend Stichting | Director | 1,150,922 |
| International Management S.A. Artal | Director | 3,006,678 |
| International S.C.A. Artal | Director | 408,435 |
| Group S.A. Artal | Director | 367,145 |
| Amaury Wittouck | Director | 3,516,214 |
| Participations S.a r.l. Artal | Director | 311,336,543 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Michael S. Exton, | $3.55M | $5.80M | $1.52M | $60 | – |
| FY2024 Lonnel Coats | $3.47M | -$884.85K | $1.60M | $39 | – |
| FY2024 Michael S.Exton Ph.D. | $2.84M | $1.62M | $1.60M | $39 | – |
| FY2023 Michael S. Exton, | $4.11M | $3.06M | $1.58M | $80 | – |
| FY2022 Lonnel Coats | $4.17M | $1.20M | $1.62M | $48 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 2, 2026, we employed 81 persons, of whom 15 hold M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 7, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 11, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 4, 2015 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 2, 2010 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 19, 2007 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 2, 2007 | Name change | Name changed from LEXICON GENETICS INC/TX to LEXICON PHARMACEUTICALS, INC./DE |
| Apr 7, 2000 | IPO | Initial public offering priced (424B4 prospectus) |